CBPartners Releases New Thought Piece on HTA in the Emerging Markets January 24, 2013
In this new economic era, how can we balance price with access?
With low-cost standard of care and a demand for real-world data, how can we effectively communicate value?
What are other governments doing to contain cost and drive local innovation - and how can we be a part of it?
Considering market and payer realities, how do we adapt and how do we value adaptation?
How do we meet our stakeholder needs given the unique nature of our brand?
International Reference Pricing: New Rules for a New Era
Cyrus A. Chowdhury
Payer Prophecy: Pricing & Access Optimisation by Trial Design
Monica Martin de Bustamante
Click here to request a copy
SCOTUS on ACA
June 29, 2012
Yesterday, on its last day in session, the US Supreme Court announced its ruling on President Obama's signature legislation, the Patient Protection and Affordable Care Act (ACA). In an unexpected move, conservative Chief Justice Roberts sided with the four generally left-leaning Justices Breyer, Ginsburg, Kagan, and Sotomayor in upholding the law and its central provision, the individual mandate for healthcare coverage. In his opinion, Chief Justice Roberts dismissed the applicability of the Commerce Clause and instead opted for a less expansive interpretation of the US Constitution, declaring... Continue
ROCHE Wins Right To Use Crenezumab in Early Intervention Study in Colombia
May 15, 2012
ROCHE has won the right to use their experimental therapy, Crenezumab, in an early intervention trial in Colombia. The study will look at a patient population suffering from early onset dementia, with some individuals developing symptoms as early as 30 years of age.
Recent efforts by drug companies have fallen earlier in the disease progression spectrum. It remains to be seen how willing payers will be to reimburse... Continue
NICE Reverses Decision on ZYTIGA Based on Updated Patient Access Scheme and New Data
May 16, 2012
It was rather unsurprising that NICE revised their original negative stance on ZYTIGA. Today, England / Wales' HTA body positively recommended ZYTIGA for use in castration-resistant metastatic prostate cancer patients following treatment with docetaxel.
Although additional data was ... Continue